Form 4: UTHR COO Sells Shares After Option Exercise

United Therapeutics Corp's President and COO, Michael Benkowitz, executed a pre-planned sale of common stock following the exercise of stock options.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), engaged in transactions on October 27, 2025, involving the exercise of stock options and subsequent sale of common stock.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan established on June 3, 2025.
• Through a trust (Trust 2), 14,625 stock options were exercised at a price of $135.42 per share, and the resulting 14,625 common shares were sold at $417.4965 per share.
• Through another trust (Trust 3), 6,125 stock options were exercised at $146.03 per share, and an additional 1,750 stock options were exercised at $146.03 per share.
• A total of 7,875 common shares from Trust 3 (6,125 + 1,750) were subsequently sold at $417.4965 per share.
• Following these transactions, Michael Benkowitz's indirect beneficial ownership through Trust 2 for common stock is 0.00 shares, with 55,875 stock options remaining.
• Indirect beneficial ownership through Trust 3 for common stock is 130 shares, with 18,375 stock options remaining from the first set of options and 0.00 options remaining from the second set.
• Direct beneficial ownership of common stock remains at 2,648 shares.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan, which is a neutral event from an investment perspective.

Positives

• The executive is realizing value from previously granted stock options, indicating a successful vesting and appreciation of the company's stock price.
• The transactions were executed under a Rule 10b5-1 trading plan, demonstrating pre-planning and adherence to insider trading regulations, which enhances transparency and reduces concerns about opportunistic selling.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, results in a reduction of their direct and indirect beneficial ownership in the company's common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences for executives in publicly traded companies across all industries, including biotechnology and pharmaceuticals. They typically reflect personal financial planning rather than a change in the company's fundamental outlook.

Comparison to Industry Standards

• Not applicable as this filing reports an individual insider transaction, not company performance or strategic initiatives that would be compared to industry benchmarks or competitors.

Related Party Transactions

• The transactions involved shares held in a trust (Trust 2) beneficially owned by the Reporting Person, where the Reporting Person and his spouse are co-trustees with shared investment and voting power.
• Additional transactions involved shares held in a trust (Trust 3) beneficially owned by the Reporting Person, where his family members are beneficiaries, and the Reporting Person has sole investment and voting power.

Stakeholder Impact

• For shareholders, this represents a routine liquidity event for a key executive, executed under a pre-arranged plan, and does not typically signal a change in the company's fundamental prospects or management's long-term view.
• The exercise of options and subsequent sale of shares is a standard component of executive compensation and personal financial management.

Key Dates

Recommendation

The filing details a pre-planned exercise of stock options and subsequent sale of shares by a key executive. This is a routine insider transaction under a Rule 10b5-1 plan, indicating a pre-scheduled liquidity event rather than a change in fundamental outlook. It does not provide new information that would warrant a change in investment recommendation.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Executive Compensation, Michael Benkowitz, 10b5-1 Plan, Biotechnology, Pharmaceuticals